Medicare AdvantageCoverageMedium impact
MA08.021c, Dofetilide (Tikosyn®) Use in the Inpatient Setting
Independence Blue Cross·Cardiology, Critical Care·Pharmacy
Effective date
Mar 5, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.021c regarding Dofetilide (Tikosyn®) use in inpatient settings has been reissued with updates. This is a fresh pharmacy policy that may affect coverage or authorization requirements for this cardiac medication in hospital billing.
Action Required
By March 5, 2025: Billing team should review the full updated policy MA08.021c for Dofetilide (Tikosyn®) inpatient use to identify any changes in coverage criteria, prior authorization requirements, or documentation needs. Update billing protocols accordingly for Medicare Advantage patients receiving this cardiac medication during inpatient stays.